Literature DB >> 20143946

Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Magdalini Moutaftsi1, David C Tscharke, Kerrie Vaughan, David M Koelle, Lawrence Stern, Mauricio Calvo-Calle, Francis Ennis, Masanori Terajima, Gerd Sutter, Shane Crotty, Ingo Drexler, Genoveffa Franchini, Jon W Yewdell, Steven R Head, Janice Blum, Bjoern Peters, Alex Sette.   

Abstract

Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20143946      PMCID: PMC3363998          DOI: 10.2217/fmb.09.110

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  110 in total

1.  Antibodies directed against an epitope in the N-terminal region of the H4L subunit of the vaccinia virus RNA polymerase inhibit both transcription initiation and transcription termination, in vitro.

Authors:  Mohamed R Mohamed; Linda A Christen; Edward G Niles
Journal:  Virology       Date:  2002-07-20       Impact factor: 3.616

2.  Protein composition of the vaccinia virus mature virion.

Authors:  Wolfgang Resch; Kim K Hixson; Ronald J Moore; Mary S Lipton; Bernard Moss
Journal:  Virology       Date:  2006-09-26       Impact factor: 3.616

3.  Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans.

Authors:  Masanori Terajima; Laura Orphin; Anita M Leporati; Pamela Pazoles; John Cruz; Alan L Rothman; Francis A Ennis
Journal:  Hum Immunol       Date:  2008-10-26       Impact factor: 2.850

4.  Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.

Authors:  Lydia Aldaz-Carroll; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Lewis K Pannell; Jacob Lebowitz; Christiana Fogg; Christine L White; Bernard Moss; Gary H Cohen; Roselyn J Eisenberg
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

5.  Disruption of MHC class II-restricted antigen presentation by vaccinia virus.

Authors:  Ping Li; Nan Wang; Delu Zhou; Christina S K Yee; Cheong-Hee Chang; Randy R Brutkiewicz; Janice S Blum
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

6.  HLA-A2-restricted human CD8(+) cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses.

Authors:  Yuzhi Dong; Thomas N Denny
Journal:  J Infect Dis       Date:  2006-06-12       Impact factor: 5.226

7.  Nucleotide sequence and transcript organization of a region of the vaccinia virus genome which encodes a constitutively expressed gene required for DNA replication.

Authors:  N A Roseman; D E Hruby
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox.

Authors:  N D Ostrout; M M McHugh; D J Tisch; A M Moormann; V Brusic; J W Kazura
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

9.  Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses.

Authors:  Masanori Terajima; John Cruz; Gregory Raines; Elizabeth D Kilpatrick; Jeffrey S Kennedy; Alan L Rothman; Francis A Ennis
Journal:  J Exp Med       Date:  2003-03-31       Impact factor: 14.307

10.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines.

Authors:  Huynh-Hoa Bui; John Sidney; Wei Li; Nicolas Fusseder; Alessandro Sette
Journal:  BMC Bioinformatics       Date:  2007-09-26       Impact factor: 3.169

View more
  42 in total

1.  Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

Authors:  M S Keckler; D S Carroll; N F Gallardo-Romero; R R Lash; J S Salzer; S L Weiss; N Patel; C J Clemmons; S K Smith; C L Hutson; K L Karem; I K Damon
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays.

Authors:  Ann L Oberg; Neelam Dhiman; Diane E Grill; Jenna E Ryan; Richard B Kennedy; Gregory A Poland
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

3.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

4.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 5.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

Authors:  D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

7.  Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.

Authors:  Marina Zaitseva; Kevin Tyler McCullough; Stephanie Cruz; Antonia Thomas; Claudia G Diaz; Laurie Keilholz; Irma M Grossi; Lawrence C Trost; Hana Golding
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

8.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

Review 9.  Design and utilization of epitope-based databases and predictive tools.

Authors:  Nima Salimi; Ward Fleri; Bjoern Peters; Alessandro Sette
Journal:  Immunogenetics       Date:  2010-03-06       Impact factor: 2.846

10.  An integrated approach to epitope analysis II: A system for proteomic-scale prediction of immunological characteristics.

Authors:  Robert D Bremel; E Jane Homan
Journal:  Immunome Res       Date:  2010-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.